8,122 results match your criteria Thyroid Medullary Carcinoma

Age-Related Changes in Calcitonin-Producing Thyroid C-Cells of Male Wistar Rats.

Microsc Microanal 2022 May 20:1-9. Epub 2022 May 20.

Department of Cytology, Institute for Biological Research "Siniša Stanković" - National Institute of the Republic of Serbia, University of Belgrade, 142 Despot Stefan Blvd., 11060 Belgrade, Serbia.

Thyroid C-cells secrete the hormone calcitonin (CT) which acts as an inhibitor of bone resorption. Our aim was to examine the age-related changes in the structure and function of CT-producing C-cells, using histomorphometric, ultrastructural, and biochemical analyses. We used young adult (3-months-old), middle-aged (16-months-old), and old (24-months-old) male rats. Read More

View Article and Full-Text PDF

Gas chromatography-mass spectrometry-based untargeted metabolomics reveals metabolic perturbations in medullary thyroid carcinoma.

Sci Rep 2022 May 19;12(1):8397. Epub 2022 May 19.

Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Medullary thyroid cancer (MTC) is a rare tumor that arises from parafollicular cells within the thyroid gland. The molecular mechanism underlying MTC has not yet been fully understood. Here, we aimed to perform plasma metabolomics profiling of MTC patients to explore the perturbation of metabolic pathways contributing to MTC tumorigenesis. Read More

View Article and Full-Text PDF

External Validation of Three Available Grading Systems for Medullary Thyroid Carcinoma in a Single Institution Cohort.

Endocr Pathol 2022 May 18. Epub 2022 May 18.

Pathology Unit, "Città Della Salute E Della Scienza" Hospital, Turin, Italy.

Medullary thyroid carcinoma (MTC) is a rare thyroid carcinoma with a variable clinical behavior. Potential clinical and pathological prognostic markers have been investigated, but studies are limited and controversial. In neuroendocrine neoplasms of various other sites, necrosis and proliferation (mitotic activity and/or Ki67 index) are integrated to provide a histological grade. Read More

View Article and Full-Text PDF

Is Encapsulated Medullary Thyroid Carcinoma Associated With a Better Prognosis? A Case Series and a Review of the Literature.

Front Endocrinol (Lausanne) 2022 27;13:866572. Epub 2022 Apr 27.

Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

Context: Medullary thyroid carcinoma (MTC) is a malignant neuroendocrine neoplasm that may spread to lymph nodes before the primary tumor is diagnosed; moreover, distant metastases are already present in about 10% of patients at diagnosis. Serum calcitonin (Ctn) usually reflects the spread of disease, thus orienting the extent of surgery and predicting the possibility of biochemical remission. Tumor size and vascular invasion are important prognostic factors, but little is known on the relationship between other histopathological features, such as the presence of a tumor capsule, and long term outcome of MTC. Read More

View Article and Full-Text PDF

Evaluation of Lipocalin-2 and Twist expression in thyroid cancers and its relationship with epithelial mesenchymal transition.

Ann Diagn Pathol 2022 May 10;59:151973. Epub 2022 May 10.

Department of Pathology, Ankara Training and Research Hospital, Ankara, Turkey.

Objective: To evaluate the expressions of lipocalin-2 (LCN-2) and Twist in thyroid cancers and examine its relationship with epithelial-to-mesenchymal transition (EMT) and clinicopathological factors.

Materials And Methods: The expression of LCN-2 and Twist was immunohistochemically evaluated in a total of 249 cases, including 120 patients with papillary thyroid carcinomas (PTC), 34 with follicular thyroid carcinoma (FTC), 15 with medullary thyroid carcinomas (MTC), 20 with non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), 47 with follicular adenomas (FA), and 13 with nodular hyperplasia (NH). In addition, the relationship between the expression of EMT markers E-cadherin and vimentin was investigated in malignant cases. Read More

View Article and Full-Text PDF

Rapid diagnosis of papillary thyroid carcinoma with machine learning and probe electrospray ionization mass spectrometry.

J Mass Spectrom 2022 Jun;57(6):e4831

Shimadzu China Innovation Center, Shimadzu Corporation, Beijing, China.

Frozen section examination could provide pathological diagnosis for surgery of thyroid nodules, which is time-consuming, skill- and experience-dependent. This study developed a rapid classification method for thyroid nodules and machine learning. Total 69 tissues were collected including 43 nodules and 26 nodule-adjacent tissues. Read More

View Article and Full-Text PDF

Grading of Medullary Thyroid Carcinoma: an Interobserver Reproducibility Study.

Endocr Pathol 2022 May 13. Epub 2022 May 13.

Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.

Grade, based on proliferative activity and tumor necrosis, has recently been shown to be prognostic in medullary thyroid carcinoma (MTC) in multivariate analysis. The aim of this study was to evaluate the interobserver reproducibility of assessed grade in MTC. Three groups (each group included one resident/fellow and one attending pathologist) independently evaluated a cohort of 44 sporadic MTC. Read More

View Article and Full-Text PDF

Brain metastasis from calcitonin-negative medullary thyroid carcinoma.

Ann Endocrinol (Paris) 2022 May 7. Epub 2022 May 7.

Department of Endocrinology, Centro Hospitalar Universitário do Porto, Portugal.

Introduction: Medullary thyroid cancer (MTC) is a primary neuroendocrine tumor derived from parafollicular cells or C-cells of the thyroid gland. It accounts for 1% to 10% of all thyroid cancers and is the second most aggressive thyroid cancer after undifferentiated thyroid carcinoma. Serum calcitonin and carcinoembryonic antigen (CEA) concentrations are widely used as biomarkers to facilitate diagnosis and follow-up. Read More

View Article and Full-Text PDF

Practical lessons from treating medullary thyroid carcinoma patients harboring a RET-alteration: Pralsetinib-induced acute confusional state.

Acta Oncol 2022 May 9:1-5. Epub 2022 May 9.

Neuroendocrine Tumor Unit, ENETS Center of Excellence, Endocrinology and Metabolism Department, Hadassah Medical Organization and Faculty of Medicine, Jerusalem, Israel.

View Article and Full-Text PDF

Diagnostic performance of next-generation sequencing and genetic profiling in thyroid nodules from a single center in China.

Eur Thyroid J 2022 Apr 1. Epub 2022 Apr 1.

X Zhu, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, China.

Objective: The data regarding the mutation landscape in Chinese patients with thyroid cancer are limited. The diagnostic performance of thyroid nodules by fine-needle aspiration (FNA) cytology needs optimization, especially in indeterminate nodules.

Methods: A total of 1039 FNA and surgical resection samples tested using the targeted multigene NGS panel were retrospectively collected. Read More

View Article and Full-Text PDF

Metastatic medullary thyroid carcinoma: a new way forward.

Endocr Relat Cancer 2022 Apr 1. Epub 2022 Apr 1.

A Grossman, Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford Medical Sciences Division, Oxford, United Kingdom of Great Britain and Northern Ireland.

Medullary thyroid carcinoma (MTC) is a rare malignancy comprising 1-2% of all thyroid cancers in the United States. Approximately 20% of cases are familial, secondary to a germline RET mutation, while the remaining 80% are sporadic, but also harbour a somatic RET mutation in more than half of all cases. Up to 15-20% of patients will present with metastatic disease, and retrospective series report a 10-year survival of 10-40% from time of first metastasis. Read More

View Article and Full-Text PDF

First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer.

Clin Nucl Med 2022 Jun 4;47(6):e444-e445. Epub 2022 Apr 4.

From the Department of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, India.

Abstract: A 56-year-old man was diagnosed with calcitonin negative, plasma chromogranin A-positive, immunohistochemistry-negative, high-grade MTC (medullary thyroid cancer) behaving clinically like anaplastic thyroid cancer and presented with progressive disease after conventional therapies. A theranostic approach of 68Ga-DOTA.SA. Read More

View Article and Full-Text PDF

The Effect of Anlotinib Combined with anti-PD-1 in the Treatment of Gastric Cancer.

Front Surg 2022 12;9:895982. Epub 2022 Apr 12.

Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, China.

Background: Protein tyrosine kinase (PTK) signaling pathway has been confirmed to be involved in the proliferation, differentiation and migration of tumor cells. Anlotinib, as a multi-target tyrosine kinase inhibitor, which can inhibit the expression of vascular endothelial growth factor receptor (VEGFR), has been confirmed to have significant therapeutic effects on non-small cell lung cancer, medullary thyroid carcinoma, and soft tissue sarcoma, but the therapeutic effect on gastric cancer (GC) is still unclear.

Methods: Anlotinib was screened out of 880 drugs through Cell Counting Kit 8 (CCK-8) technology. Read More

View Article and Full-Text PDF

Prospective study on the clinical relevance of F-DOPA positron emission tomography/computed tomography in patients with medullary thyroid carcinoma.

Endocrine 2022 Apr 30. Epub 2022 Apr 30.

Molecular Imaging and Metabolic Therapy Section. Imaging Department, University Hospital CEMIC, Galván 4102. CP 1414, Ciudad Autónoma de Buenos Aires, Argentina.

Purpose: F-DOPA Positron Emission Tomography/Computed Tomography (F-DOPA PET/CT) is a sensitive functional imaging method (65-75%) for detecting disease localization in medullary thyroid cancer (MTC). We aimed: (i) to assess the clinical usefulness of F-DOPA PET/CT in patients with MTC and elevated calcitonin (Ctn) and CEA levels and, (ii) to evaluate changes in disease management secondary to the findings encountered with this methodology.

Methods: Thirty-six patients with MTC and Ctn levels ≥150 pg/ml were prospectively included. Read More

View Article and Full-Text PDF

Metastasis of lung carcinoid in the thyroid gland after 18 years: it is never too late. A case report and review of the literature.

Pathologica 2022 Apr;114(2):164-169

Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.

Metastasis to the thyroid gland is a rare event. To date, only 11 cases of metastasis from neuroendocrine tumors (NETs) originating in the lung have been reported. We present a case of a patient in his 40s harboring two nodules in the thyroid gland that were diagnosed as well-differentiated NET (G1). Read More

View Article and Full-Text PDF

Medullary thyroid carcinoma diagnosed with liquid-based cytology and immunocytochemistry.

J Immunoassay Immunochem 2022 Apr 27:1-14. Epub 2022 Apr 27.

Department of Cytopathology, "Venizeleio-Pananeio" General Hospital, Heraklion, Crete, Greece.

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine malignancy that arises from the parafollicular cells (C cells) secreting calcitonin. This study summarizes our experience in the diagnosis of MTC with ultrasound-guided thyroid FNA, subsequently processed with liquid-based cytology (LBC) and immunocytochemistry (ICC). We searched our laboratory archives for thyroid FNA cases with an interpretation of positive or suspicious for MTC, during the period 2004-2018. Read More

View Article and Full-Text PDF

Pre- And Post-Operative Circulating Tumoral Dna In Patients With Medullary Thyroid Carcinoma.

J Clin Endocrinol Metab 2022 Apr 26. Epub 2022 Apr 26.

Unit of Endocrinology, Department of Clinical and Experimental Medicine, University-Hospital of Pisa, 56124 Pisa, Italy.

Context: Measurement of driver mutations in circulating tumoral DNA (ctDNA) obtained by liquid biopsy has been shown to be a sensitive biomarker in several human tumors.

Objective: The aim of this study was to evaluate the clinical relevance of pre- and post-operative ctDNA in sporadic medullary thyroid cancer (sMTC).

Methods: We studied pre- and post-operative ctDNA in 26 and 23 sMTC patients, respectively. Read More

View Article and Full-Text PDF

Metastatic Neuroendocrine Tumors to Parotid Gland: Where Do They Come From?

Int J Surg Pathol 2022 Apr 24:10668969221095267. Epub 2022 Apr 24.

Department of Pathology, 2468Rush University Medical Center, Chicago, Illinois, USA.

. Metastasis to parotid gland occurs mostly from skin cancers of the head and neck region. Metastatic neuroendocrine tumors to the parotid gland are rare and not well studied so far. Read More

View Article and Full-Text PDF

Editorial: Non-Syndromic Familial Non-Medullary Thyroid Carcinoma: Clinical and Genetic Update.

Front Endocrinol (Lausanne) 2022 6;13:891903. Epub 2022 Apr 6.

Department of Medical, Surgical and Neurological Sciences, University of Siena, Siena, Italy.

View Article and Full-Text PDF

An Audit of Systemic Therapy in Medullary Carcinoma Thyroid.

Indian J Surg Oncol 2022 Mar 15;13(1):61-67. Epub 2021 Aug 15.

Department of Medical Oncology, Tata Memorial Hospital, Parel, Mumbai 400012 India.

There is a paucity of evidence of the impact of sorafenib on MCT and it is the preferred therapy used in India. We decided to do an audit of all patients of MCT who were referred to us for systemic therapy. The objective of this exercise was to identify the treatment pattern, outcomes, and adverse events with therapy in MCT. Read More

View Article and Full-Text PDF

Medullary Thyroid Carcinoma Mutational Spectrum Update and Signaling-Type Inference by Transcriptional Profiles: Literature Meta-Analysis and Study of Tumor Samples.

Cancers (Basel) 2022 Apr 13;14(8). Epub 2022 Apr 13.

Molecular Mechanisms Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy.

Medullary thyroid carcinoma (MTC) is a rare but aggressive tumor. Although and genes are recognized drivers in MTC, associated downstream signaling pathways are largely unknown. In this study, we report 17 sporadic MTCs, collected at our institution, comprising patient-matched primary and lymph node metastatic tumors investigated for mutational and transcriptional profiles. Read More

View Article and Full-Text PDF

Risk of malignancy in thyroid nodules with indeterminate (THY3f) cytology.

Ann R Coll Surg Engl 2022 Apr 21. Epub 2022 Apr 21.

Oxford University Hospitals NHS Foundation Trust, UK.

Background: Fine-needle aspiration cytology (FNAC) is an integral part of thyroid nodule assessment. Nodules with an indeterminate cytology (THY3a-f) require formal histological assessment to confirm benign or malignant pathology. This study aimed to provide data for an evidence-based approach for management of patients with THY3f nodules. Read More

View Article and Full-Text PDF

Evaluation of multinodular goiter and primary hyperparathyroidism leads to a diagnosis of AL amyloidosis.

Thyroid Res 2022 Apr 20;15(1). Epub 2022 Apr 20.

Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL, USA.

Background: Amyloid goiter, defined as excess amyloid within the thyroid gland in such quantities that it produces a clinically apparent goiter, is a very rare manifestation of systemic amyloidosis with cases commonly seen in the setting of Amyloid A (AA) amyloidosis. Amyloid goiter as the primary clinical manifestation secondary to Amyloid light chain (AL) amyloidosis is very rare. We present a case of AL amyloidosis with initial manifestation as goiter with amyloid deposition in the thyroid and the parathyroid gland. Read More

View Article and Full-Text PDF

Effect of Vandetanib Treatment on Cystic Changes in the Liver following Metastasis from Medullary Thyroid Carcinoma.

Case Rep Endocrinol 2022 6;2022:9855403. Epub 2022 Apr 6.

Department of Breast and Endocrine Surgery, Kanagawa Cancer Center, Yokohama, Japan.

A number of causes are responsible for the development of cystic lesions in the liver. However, metastasis is a rare cause, and cystic metastasis from medullary thyroid carcinoma has not yet been reported. A 46-year-old Japanese man presented to our hospital with a mass in the left side of his neck. Read More

View Article and Full-Text PDF

CpG Island Methylation of the Rap1Gap Gene in Medullary Thyroid Cancer.

Arch Iran Med 2022 Mar 1;25(3):171-177. Epub 2022 Mar 1.

Cellular and Molecular Research Center, Medical Basic Sciences Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background: Medullary thyroid cancer (MTC) is a rare type of neuroendocrine tumor. This study aimed to investigate the gene and protein expression of and DNA methylation patterns of its CpG74 , CpG74 , and CpG24 in an Iranian population with MTC.

Methods: In this case-control study, we selected 55 individuals who underwent thyroidectomy in Erfan hospital, Tehran, between 2018 and 2020. Read More

View Article and Full-Text PDF

"Incidentally discovered medullary thyroid carcinoma in the post-operative Graves' patient - A case report".

Am J Otolaryngol 2022 Apr 5;43(3):103450. Epub 2022 Apr 5.

Department of Otolaryngology - Head and Neck Surgery, University of Missouri School of Medicine, 1 Hospital Drive, Columbia, MO 65212, United States of America.

Objective: To report a very rare case of incidentally discovered Medullary Thyroid Carcinoma after total thyroidectomy in a patient with Graves' disease, review available literature, and present readers with management information.

Results: Medullary Thyroid Carcinoma in the setting of Graves' disease is a rare scenario. Only fifteen total cases besides ours has been described in literature, and only six other cases were incidentally discovered. Read More

View Article and Full-Text PDF

Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.

Front Endocrinol (Lausanne) 2022 29;13:864253. Epub 2022 Mar 29.

Department of Clinical and Experimental Medicine, Endocrine Unit, University Hospital of Pisa, Pisa, Italy.

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignant tumor originating from parafollicular C-cells producing calcitonin. Most of cases (75%) are sporadic while the remaining (25%) are hereditary. In these latter cases medullary thyroid carcinoma can be associated (multiple endocrine neoplasia type IIA and IIB) or not (familial medullary thyroid carcinoma), with other endocrine diseases such as pheochromocytoma and/or hyperparathyroidism. Read More

View Article and Full-Text PDF

Suboptimal accuracy of ultrasound and ultrasound-based risk stratification systems in detecting medullary thyroid carcinoma should not be overlooked. Findings from a systematic review with meta-analysis.

Clin Endocrinol (Oxf) 2022 Apr 13. Epub 2022 Apr 13.

Servizio di Endocrinologia e Diabetologia, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland.

Objective: Ultrasound (US) is the pivotal procedure during the diagnostic work-up of thyroid nodule and several US-based risk stratification systems (RSSs) have been recently developed. Since the performance of RSSs in detecting medullary thyroid carcinoma (MTC) has been rarely investigated, the present systematic review aimed to achieve high evidence about (1) how MTC is classified according to RSSs; (2) if RSSs correctly classify MTC at high risk/suspicion, and (3) if MTC is classified as suspicious at US when RSSs are not used.

Design: The review was performed according to MOOSE. Read More

View Article and Full-Text PDF

Diagnostic Utility of Procalcitonin for Sporadic Medullary Thyroid Carcinoma in Patients with Nodular Disease and Mild or Moderate Hypercalcitoninemia.

Horm Metab Res 2022 Apr 12;54(4):220-223. Epub 2022 Apr 12.

Faculdade Santa Casa de Belo Horizonte, Minas Gerais, Brazil.

Many authors recommend the measurement of serum calcitonin (Ctn) to screen for sporadic medullary thyroid carcinoma (MTC) in patients with thyroid nodules. In this situation, procalcitonin (pro-Ctn) would have greater utility in patients with hypercalcitoninemia<100 pg/ml. The aim of this study was to evaluate the utility of pro-Ctn in patients with thyroid nodules and without a suspicion of familial MTC or type 2 multiple endocrine neoplasia who had mild or moderate hypercalcitoninemia without an apparent cause. Read More

View Article and Full-Text PDF